The OCMX™ is pleased to announce the listing of KometaBio to its online portal which offers Investors and Advisors the ability to learn more about this exciting opportunity.

FORT LEE, NJ, July 12, 2021 /24-7PressRelease/ — In 2016, KometaBio Inc. disrupted the bone grafting industry with its device that converts extracted teeth into bone graft that can be immediately used for the same patient. Utilizing patients own tissue for bone augmentation procedures is the GOLD standard in Dentistry and Orthopedics. Now, extracted teeth are no longer wasted, but utilized for predictable and exceptional results. KometaBio is the first major player to capture the untapped autologous bone graft market in Dentistry, estimated to reach $735 million in the next 2-3 years.

The OCMX™ is pleased to announce the listing of KometaBio to its online portal which offers Investors and Advisors the ability to learn more about this exciting opportunity.

The OCMX™ has spent considerable time completing its due diligence on KometaBio and concluded that there is indeed a tremendous potential for this opportunity.

The OCMX™ noted that KometaBio exhibits the main components of any solid opportunity, namely a solid management team, a great track record, and a number of key competitive advantages.


Our technology provides the patient with low cost and high-performance bone graft for any bone substitute indication. The graft is converted from their own extracted tooth therefore offering a much more natural, biological, highly bioactive substance that performs a lot better and much more predictably than any artificial synthetic bone graft material, allograft, or xenograft on the market.

Our award-winning device, the Smart Dentin Grinder, is distributed in 26 countries. KometaBio is currently expanding its footprint in Dental and making its initial inroads into the Orthopedic space.


We believe that in the next few years, our flagship product, the Smart Dentin Grinder, will be offered in every major clinic where teeth are extracted or bone graft is utilized (with or without dental implants). Our technology will allow us to capture a substantial portion of the autologous graft market. The company plans to boost its marketing strategy to be able to cover a much wider audience as well as directly educate the patients.

We intend to accelerate efforts to enter the Orthopedic market where a need for a bone mill that better aligns with the surgical workflow is needed. Implementing these plans will position KometaBio as one of the fastest growing medical device companies in the Dental and Orthopedic space and will place us well for a potential acquisition.


KometaBio presents a substantial upside with limited risk for the following reasons:

• KometaBio is the only player who is best positioned to become the dominant player in the lucrative and sought after autologous bone segment.
• The product is already well accepted (over 50,000 surgical procedures done to date)
• The company utilizes a proven recurring revenue model that is structured around a disposable per patient product business.
• KometaBio holds substantial R&D strength led by Prof. Itzhak Binderman, a world renown expert in tissue engineering.
• KometaBio amassed an impressive list of Key Opinion Leaders in the field
• The company has been profitable for the past 4 years and demonstrates revenue growth with a solid cash position.


Amit Binderman, CEO
Holds a BSC in sciences and MBA from UC Berkeley, highly experienced senior executive managing sales and business development for large companies as well as start-ups. Extensive dental and medical device experience.

Prof. Itzhak Binderman, R&D
With over 125 publications under his belt, Prof. Binderman is a world renown scientist and top expert in the field of bone regeneration. Advisor to some leading regenerative biomaterial and implant companies. Oral surgeon.


The OCMX™ , established in 2009, is a next generation investor relations and marketing outreach firm. Through our online Ocmx portal, we connect companies with financial networks, generating interest and awareness for their opportunity.

Contact Us
TD Canada Trust Tower
161 Bay Street, 45th Floor
Toronto, Ontario, M5J 2S1
Tel: 1-866-209-6862
Email: [email protected]

KometaBio gets listed on THE OCMX™

For the original version of this press release, please visit here